Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has provided an update.
MindBio Therapeutics Corp. has successfully passed a mandatory independent safety audit in its Phase 2B clinical trials, which are testing their lead candidate MB22001 in patients with Major Depressive Disorder and those with Advanced Stage Cancer. The trials, which allow patients to administer MB22001 at home, have shown no serious adverse effects, supporting the drug’s potential as a scalable alternative to traditional anti-depressants. This positive outcome confirms earlier trial results and positions the company to continue its innovative approach in psychiatric treatment, with plans to complete the trials by late 2025.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical stage biopharmaceutical company focused on psychiatric medicine development, specifically using microdoses of psychedelic medicines to treat depressive disorders. The company aims to compete directly with first-line anti-depressant medications by offering a non-hallucinogenic psychedelic treatment.
YTD Price Performance: 25.00%
Average Trading Volume: 129,446
Technical Sentiment Consensus Rating: Buy
Learn more about MBIO stock on TipRanks’ Stock Analysis page.